Stay updated on Filgotinib Combo in RA Patients Inadequate Response Clinical Trial
Sign up to get notified when there's something new on the Filgotinib Combo in RA Patients Inadequate Response Clinical Trial page.

Latest updates to the Filgotinib Combo in RA Patients Inadequate Response Clinical Trial page
- Check5 days agoChange DetectedAdded the topic Rheumatoid arthritis and linked related topics such as MedlinePlus Genetics. Updated the page revision from v3.4.1 to v3.4.2.SummaryDifference0.1%

- Check12 days agoChange DetectedAdded Revision: v3.4.1 and removed related topics including Rheumatoid arthritis and MedlinePlus Genetics, and removed Revision: v3.4.0 from the related topics.SummaryDifference0.1%

- Check19 days agoChange DetectedLocation entry updated from Gurgaon, India to Gūrgaon, India in the study locations list to reflect a transliteration/spelling variation of the same city.SummaryDifference0.0%

- Check26 days agoChange DetectedGlossary toggle is displayed and QC/Fear Act labels and the page revision have been updated to reflect the new wording and version (Last Update Submitted that Met QC Criteria, No FEAR Act Data, Revision: v3.4.0), replacing the prior QC label, No FEAR Act data, and Revision: v3.3.4.SummaryDifference0.1%

- Check33 days agoChange DetectedAdded Rheumatoid arthritis as a topic and MedlinePlus Genetics as related topics. Revision updated from v3.3.3 to v3.3.4; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check47 days agoChange DetectedThe Rheumatoid arthritis topic and the related MedlinePlus Genetics topics were removed from the page. This metadata change may affect search indexing and topic categorization but does not alter the trial details.SummaryDifference0.0%

Stay in the know with updates to Filgotinib Combo in RA Patients Inadequate Response Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Filgotinib Combo in RA Patients Inadequate Response Clinical Trial page.